Published in Biochemistry on June 16, 2009
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Organometallic anticancer compounds. J Med Chem (2010) 2.19
Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc (2011) 1.11
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92
Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol (2011) 0.91
Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling. Sci Rep (2013) 0.90
Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3β. J Biol Inorg Chem (2010) 0.86
Identification of a novel family of BRAF(V600E) inhibitors. J Med Chem (2012) 0.85
In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J Med Chem (2014) 0.82
An organometallic inhibitor for the human repair enzyme 7,8-dihydro-8-oxoguanosine triphosphatase. Angew Chem Int Ed Engl (2013) 0.81
Expression and purification of active receptor interacting protein 1 kinase using a baculovirus system. Protein Expr Purif (2013) 0.80
Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Org Biomol Chem (2012) 0.78
Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands. Eur J Inorg Chem (2015) 0.77
In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database. J Mol Model (2015) 0.77
Development of organometallic S6K1 inhibitors. J Med Chem (2014) 0.76
Somatic DNA mutation analysis in targeted therapy of solid tumours. Transl Pediatr (2015) 0.76
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr (2004) 31.52
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science (1991) 13.85
Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science (1991) 9.99
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A (1983) 4.82
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J (1999) 2.79
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res (2003) 2.44
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res (2006) 2.31
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem (2006) 1.94
Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol (1995) 1.87
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Nucleotide sequence of avian retroviral oncogene v-mil: homologue of murine retroviral oncogene v-raf. Nature (1984) 1.68
Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611. Nature (1984) 1.56
Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl (2006) 1.54
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent. Bioorg Med Chem Lett (2004) 1.51
Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J Am Chem Soc (2006) 1.45
Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3. Chembiochem (2006) 1.44
The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras. Mol Cell Biol (1994) 1.29
Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev (2000) 1.23
Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand. Org Biomol Chem (2007) 1.16
Association of MEK1 with p21ras.GMPPNP is dependent on B-Raf. Mol Cell Biol (1994) 1.13
Partial purification of a mitogen-activated protein kinase kinase activator from bovine brain. Identification as B-Raf or a B-Raf-associated activity. J Biol Chem (1994) 1.12
An organometallic inhibitor for glycogen synthase kinase 3. J Am Chem Soc (2004) 1.11
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem Biol (2008) 1.09
The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett (2005) 1.07
Switching on a signaling pathway with an organoruthenium complex. Angew Chem Int Ed Engl (2005) 1.02
Platinum complex as a nanomolar protein kinase inhibitor. Inorg Chem (2007) 0.93
Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen. J Biomol Screen (2005) 0.88
Coexpression analysis of human genes across many microarray data sets. Genome Res (2004) 9.38
Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell (2006) 5.40
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science (2009) 4.45
Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res (2004) 4.33
Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol (2010) 3.38
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature (2008) 2.83
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2008) 2.75
The catalytic mechanism of the ESA1 histone acetyltransferase involves a self-acetylated intermediate. Nat Struct Biol (2002) 2.56
Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci (2005) 1.91
Fungal Rtt109 histone acetyltransferase is an unexpected structural homolog of metazoan p300/CBP. Nat Struct Mol Biol (2008) 1.89
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Structural basis for nicotinamide inhibition and base exchange in Sir2 enzymes. Mol Cell (2007) 1.77
Structural basis for ubiquitin recognition by the Otu1 ovarian tumor domain protein. J Biol Chem (2008) 1.75
Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol (2010) 1.73
Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr Opin Struct Biol (2008) 1.72
Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc Natl Acad Sci U S A (2003) 1.68
Progress toward an expanded eukaryotic genetic code. Chem Biol (2003) 1.66
Iridium complex with antiangiogenic properties. Angew Chem Int Ed Engl (2010) 1.64
Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem (2005) 1.61
Structure of the p53 core domain dimer bound to DNA. J Biol Chem (2006) 1.60
Structure and autoregulation of the yeast Hst2 homolog of Sir2. Nat Struct Biol (2003) 1.59
Structure of a human ASF1a-HIRA complex and insights into specificity of histone chaperone complex assembly. Nat Struct Mol Biol (2006) 1.58
Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation (2007) 1.58
Structure of the yeast Hst2 protein deacetylase in ternary complex with 2'-O-acetyl ADP ribose and histone peptide. Structure (2003) 1.55
Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification. Structure (2008) 1.55
Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl (2006) 1.54
Maintenance of low histone ubiquitylation by Ubp10 correlates with telomere-proximal Sir2 association and gene silencing. Mol Cell (2005) 1.51
Transurethral vapor enucleation and resection of the prostate with plasma vaporization button electrode for the treatment of benign prostatic hyperplasia: a feasibility study. J Endourol (2012) 1.50
Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor. Genes Dev (2007) 1.49
Structural basis for histone and phosphohistone binding by the GCN5 histone acetyltransferase. Mol Cell (2003) 1.47
Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetylases. Proc Natl Acad Sci U S A (2004) 1.45
Milk consumption and bladder cancer risk: a meta-analysis of published epidemiological studies. Nutr Cancer (2011) 1.45
Influence of E3 region on conditionally replicative adenovirus mediated cytotoxicity in hepatocellular carcinoma cells. Cancer Biol Ther (2009) 1.45
Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J Am Chem Soc (2006) 1.45
Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3. Chembiochem (2006) 1.44
Structure and function of the SWIRM domain, a conserved protein module found in chromatin regulatory complexes. Proc Natl Acad Sci U S A (2006) 1.44
A mechanism-based inactivator for histone demethylase LSD1. J Am Chem Soc (2006) 1.43
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol (2009) 1.43
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
Structure and mechanism of lysine-specific demethylase enzymes. J Biol Chem (2007) 1.40
A simple glycol nucleic acid. J Am Chem Soc (2005) 1.37
Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe (2008) 1.35
Identification of catalytic residues in the As(III) S-adenosylmethionine methyltransferase. Biochemistry (2012) 1.32
Structure and substrate binding properties of cobB, a Sir2 homolog protein deacetylase from Escherichia coli. J Mol Biol (2004) 1.31
A modular synthesis of the lamellarins: total synthesis of lamellarin G trimethyl ether. J Org Chem (2004) 1.30
Arsenic biotransformation and volatilization in transgenic rice. New Phytol (2011) 1.29
MYST protein acetyltransferase activity requires active site lysine autoacetylation. EMBO J (2011) 1.29
Structure of Vps75 and implications for histone chaperone function. Proc Natl Acad Sci U S A (2008) 1.27
14-3-3 interaction with histone H3 involves a dual modification pattern of phosphoacetylation. Mol Cell Biol (2008) 1.27
Structural basis for sirtuin function: what we know and what we don't. Biochim Biophys Acta (2009) 1.26
Structure and activity of enzymes that remove histone modifications. Curr Opin Struct Biol (2005) 1.24
Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. Biochem Pharmacol (2010) 1.24
Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells. Mol Cell Biol (2008) 1.23
Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc Natl Acad Sci U S A (2002) 1.22
Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc (2008) 1.21
Ruthenium-induced allylcarbamate cleavage in living cells. Angew Chem Int Ed Engl (2006) 1.20
Metal complex catalysis in living biological systems. Chem Commun (Camb) (2013) 1.20
Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci (2009) 1.17
Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand. Org Biomol Chem (2007) 1.16
Structural basis for dimerization in DNA recognition by Gal4. Structure (2008) 1.16
Molecular basis for N-terminal acetylation by the heterodimeric NatA complex. Nat Struct Mol Biol (2013) 1.16
Identification of FAD2 and FAD3 genes in Brassica napus genome and development of allele-specific markers for high oleic and low linolenic acid contents. Theor Appl Genet (2012) 1.16
Site-specific introduction of an acetyl-lysine mimic into peptides and proteins by cysteine alkylation. J Am Chem Soc (2010) 1.15
Structure of a Sir2 substrate, Alba, reveals a mechanism for deacetylation-induced enhancement of DNA binding. J Biol Chem (2003) 1.14
Mapping of quantitative trait loci and development of allele-specific markers for seed weight in Brassica napus. Theor Appl Genet (2010) 1.14
Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun (2012) 1.14
Biochemical analysis of MST1 kinase: elucidation of a C-terminal regulatory region. Biochemistry (2008) 1.14
Nuclear export modulates the cytoplasmic Sir2 homologue Hst2. EMBO Rep (2006) 1.12
Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex. Blood (2010) 1.11
Biotransformation and volatilization of arsenic by three photosynthetic cyanobacteria. Plant Physiol (2011) 1.11
Molecular basis for Gcn5/PCAF histone acetyltransferase selectivity for histone and nonhistone substrates. Biochemistry (2003) 1.11
An organometallic inhibitor for glycogen synthase kinase 3. J Am Chem Soc (2004) 1.11
Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc (2011) 1.11
The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol (2008) 1.11
Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun (2008) 1.11
Structure of a ternary Naa50p (NAT5/SAN) N-terminal acetyltransferase complex reveals the molecular basis for substrate-specific acetylation. J Biol Chem (2011) 1.11
SIRT1 contains N- and C-terminal regions that potentiate deacetylase activity. J Biol Chem (2011) 1.09
FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem (2013) 1.09
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem Biol (2008) 1.09
Structure of the Rtt109-AcCoA/Vps75 complex and implications for chaperone-mediated histone acetylation. Structure (2011) 1.07
Structure and dimerization of the kinase domain from yeast Snf1, a member of the Snf1/AMPK protein family. Structure (2006) 1.07
Duplex structure of a minimal nucleic acid. J Am Chem Soc (2008) 1.06
Fluorescence-topographic NSOM directly visualizes peak-valley polarities of GM1/GM3 rafts in cell membrane fluctuations. J Lipid Res (2008) 1.06
Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1. J Virol (2005) 1.06
The human monocytic leukemia zinc finger histone acetyltransferase domain contains DNA-binding activity implicated in chromatin targeting. J Biol Chem (2007) 1.05
Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA. J Virol (2012) 1.05
Multiple roles for acetylation in the interaction of p300 HAT with ATF-2. Biochemistry (2007) 1.05
Advances in atomic gyroscopes: a view from inertial navigation applications. Sensors (Basel) (2012) 1.04
Prediction of protein structural class with Rough Sets. BMC Bioinformatics (2006) 1.04